EUCTR2004-002102-30-IT进行中（未招募）不适用
OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 738
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISAtopic dermatitisEUCTR2019-004301-28-PLDermira, Inc., a wholly owned subsidiary of Eli Lilly and Company200
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-DEForesee Pharmaceuticals Co., Ltd.137
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-SKForesee Pharmaceuticals Co., Ltd.133
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-LTForesee Pharmaceuticals Co., Ltd.133
进行中（未招募）
1 期
A clinical trial for advanced prostatic cancer patients . The study medication will be Leuprolide Mesylate, which will be administered as an injection twice. Both the study doctors and clinical trial participants know which treatment is being administered, there will be only one treatment group.The safety and efficacy of the medicinal product will be tested during the study.Advanced Prostate CarcinomaMedDRA version: 19.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 100000004864EUCTR2013-001790-25-ATForesee Pharmaceuticals Co., Ltd.133